Your AI-Trained Oncology Knowledge Connection!

Tina Cascone, MD, PhD

home / authors / tina-cascone-md-phd

Tina Cascone, MD, PhD, is an associate professor in the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center.

Articles

Dr Cascone on Evaluating Neoadjuvant Durvalumab-Based Regimens in Resectable NSCLC

Tina Cascone, MD, PhD

February 6th 2025

Tina Cascone, MD, PhD, discusses the efficacy and safety of neoadjuvant durvalumab plus novel agents or chemotherapy in resectable NSCLC.

Practice Pearls for Community Oncologists Treating Early-Stage NSCLC

Tina Cascone, MD, PhD;Sandip Patel, MD;Benjamin Levy, MD;David H. Harpole Jr, MD

August 3rd 2023

A panel of experts share unmet needs and clinical practice pearls for community oncologists regarding the treatment of patients with early-stage NSCLC.

$Treatment for Patients Unsuitable for or Refractory to Consolidation Durvalumab$

Treatment for Patients Unsuitable for or Refractory to Consolidation Durvalumab

Tina Cascone, MD, PhD;Sandip Patel, MD;Benjamin Levy, MD;David H. Harpole Jr, MD

August 3rd 2023

Tina Cascone, MD, Ben Levy, MD, and Sandip Patel, MD, offer insights into the treatment approach in patients with unresectable early-stage NSCLC who are unsuitable for consolidation durvalumab or who progress on consolidation durvalumab.

Consolidation Immunotherapy in Unresectable Early NSCLC: Novel Approaches

Tina Cascone, MD, PhD;Sandip Patel, MD;Benjamin Levy, MD;David H. Harpole Jr, MD

July 28th 2023

Sandip Patel, MD, shares his expert perspectives on novel combination consolidation immunotherapy regimens that are under evaluation in unresectable early-stage NSCLC.

Consolidation Immunotherapy in Unresectable Early NSCLC: PACIFIC Study

Tina Cascone, MD, PhD;Sandip Patel, MD;Benjamin Levy, MD;David H. Harpole Jr, MD

July 20th 2023

Ben Levy, MD, reviews the 5-year update and clinical implications of the PACIFIC study which evaluated consolidation immunotherapy in unresectable early-stage NSCLC.

Treatment Strategy in Patients with Unresectable Stage I-III NSCLC

Tina Cascone, MD, PhD;Sandip Patel, MD;Benjamin Levy, MD;David H. Harpole Jr, MD

July 20th 2023

Expert panelists discuss the characterization of patients with unresectable, early-stage NSCLC and what their standard treatment approach is for this patient population.

Adjuvant Therapy in NSCLC: IMPower-010 and KEYNOTE-091 Studies

Tina Cascone, MD, PhD;Sandip Patel, MD;Benjamin Levy, MD;David H. Harpole Jr, MD

July 13th 2023

Sandip Patel, MD, and Ben Levy, MD, discuss the results and clinical implications of the IMPower-010 and KEYNOTE-091 studies of adjuvant immunotherapy in NSCLC.

Neoadjuvant Versus Adjuvant Therapy in Resectable NSCLC

Tina Cascone, MD, PhD;Sandip Patel, MD;Benjamin Levy, MD;David H. Harpole Jr, MD

July 13th 2023

A panel of experts offers their insights into which patients with resectable early-stage NSCLC might be suitable for neoadjuvant versus adjuvant chemoimmunotherapy.

Neoadjuvant Versus Perioperative Therapy in Resectable NSCLC

Tina Cascone, MD, PhD;Sandip Patel, MD;Benjamin Levy, MD;David H. Harpole Jr, MD

July 6th 2023

Expert perspectives on selecting between neoadjuvant and perioperative chemoimmunotherapy in patients with resectable early-stage NSCLC.

Perioperative Treatment in Early NSCLC: KEYNOTE-671 and NEOTORCH Studies

Tina Cascone, MD, PhD;Sandip Patel, MD;Benjamin Levy, MD;David H. Harpole Jr, MD

July 6th 2023

Sandip Patel, MD, reviews the study design, results and clinical implications of the KEYNOTE-671 and NEOTORCH studies that evaluated perioperative chemoimmunotherapy in the treatment of early-stage NSCLC.

Perioperative Treatment in Early-Stage NSCLC: AEGEAN Study

Tina Cascone, MD, PhD;Sandip Patel, MD;Benjamin Levy, MD;David H. Harpole Jr, MD

June 29th 2023

David Harpole, MD, discusses study design, results and clinical implications of the AEGEAN study of perioperative immunotherapy (neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in the treatment of early-stage NSCLC

Neoadjuvant Therapy in Early-Stage NSCLC: CheckMate-816 Study

Tina Cascone, MD, PhD;Sandip Patel, MD;Benjamin Levy, MD;David H. Harpole Jr, MD

June 29th 2023

Overview and clinical implications of the CheckMate-816 study of neoadjuvant nivolumab plus platinum chemotherapy versus chemotherapy alone in early-stage NSCLC.

Selecting Optimal Treatment in Early-Stage NSCLC

Tina Cascone, MD, PhD;Sandip Patel, MD;Benjamin Levy, MD;David H. Harpole Jr, MD

June 23rd 2023

Ben Levy, MD offers insight into how he approaches the selection of the optimal treatment strategy in early-stage non-small cell lung cancer.

Overview of Early-Stage NSCLC and Molecular Testing

Tina Cascone, MD, PhD;Sandip Patel, MD;Benjamin Levy, MD;David H. Harpole Jr, MD

June 23rd 2023

A panel of experts who treat patients with non-small cell lung cancer provides an overview of staging, molecular testing and treatment options in stage I-IIIB non-small cell lung cancer.